An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study

Overview of attention for article published in The Journal of Headache and Pain, March 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

news: 3 news outlets
policy: 1 policy source

twitter: 3 X users

Citations

dimensions_citation: 65 Dimensions

Readers on

mendeley: 86 Mendeley

Summary News Policy documents X Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Galcanezumab for preventing migraine : Committee papers

Cited by National Institute for Health and Care Excellence on 08 Oct 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Fremanezumab for preventing migraine : Final appraisal determination committee papers

Cited by National Institute for Health and Care Excellence on 05 Mar 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.